Cherrier et al. performed a comparative whole-brain mapping analysis on nine men with prostate cancer and a rising PSA after primary therapy who were then given ADT (flutamide and leuprolide) for 9 months [130]. This evidence concerns the gene PROS1 and prostate carcinoma.